Evidence map›Paper›PMID 26887593›Full record

ArticleDrug delivery and translational research2016

Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions.

A Ramtin, A Seyfoddin, F P Coutinho, G I N Waterhouse, I D Rupenthal, D Svirskis

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

A RamtinSchool of Pharmacy, The University of Auckland, Auckland, New Zealand.
A SeyfoddinSchool of Pharmacy, The University of Auckland, Auckland, New Zealand.
F P CoutinhoBuchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand.
G I N WaterhouseSchool of Chemical Sciences, The University of Auckland, Auckland, New Zealand.
I D RupenthalBuchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand.
D SvirskisSchool of Pharmacy, The University of Auckland, Auckland, New Zealand. d.svirskis@auckland.ac.nz.ORCID 0000-0001-9435-1773
University of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) and diabetic macular edema (DME) are common causes of blindness in people aged over 55 years. Current treatment involves frequent intravitreal administration of corticosteroids such as dexamethasone. The aim of this research was to formulate an electrically controlled delivery system for dexamethasone. Polypyrrole (PPy) was polymerized with dexamethasone sodium phosphate (Dex-P) through two approaches. Firstly, conventional films (CFs) of PPy were electropolymerized by applying a constant current density of 2 mA/cm

Indexed as

Drug Delivery SystemsCell LineCell SurvivalDelayed-Action PreparationsDexamethasoneDrug LiberationElectrochemistryHumansMacular DegenerationMacular EdemaPolymerizationPolymersPyrrolesDelayed-Action PreparationsDexamethasonePolymerspolypyrrolePyrrolesConducting polymerElectrically triggered releaseOcular implantSequential polymerizationSmart materialsSolvent washing

Identifiers

PMID26887593
OpenAlexW2287495116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.